|
Evidence
from multiple studies supports quality implantation
as a
decisive factor in determining outcomes7
In separate reports…
• Patients receiving the prescription dose to
90% of the prostate gland experienced
freedom from biochemical failure8
• Prescription dose was often not achieved because
of inaccurate seed placement1
— lower doses were associated with inferior outcomes9
“A technique that increases the likelihood
of achieving adequate radiation
dose of the prostate gland should result in improved
disease control.”1
For improved dosimetry and reduced
seed migration1,10
RAPID Strand allows for the placement of sources
outside of the prostate gland without the concern of
seed migration1
• RAPID Strand helps minimize seed migration
and misplacement at the periphery of the prostate gland11
• No seed migration was observed in patients treated
with RAPID Strand1
• RAPID Strand can be implanted in periprostatic
tissue12
• Partin et al report between 40% and 50% of patients
with prostate cancer harbor ECE at the time of surgery15
 |
Treating the prostate with a
3-5 mm margin by brachytherapy
would encompass all known tumors
in approximately 99% of the
specimens examined with
extraprostatic extension.14
|
Rely on RAPID Strand for improved dosimetric coverage,
reduced seed migration and treatment of patients at
risk of ECE.1,7-9
RAPID
Strand Technical Data Sheet
REFERENCES
1. Lee WR, deGuzman AF, Tomlinson SK, McCullough DL.
Radioactive sources embedded in suture are associated
with improved postimplant dosimetry in men treated with
prostate brachytherapy. Radiat and Oncol. 2002;65:123-127.
2. Ragde H, Elgamal A-AA, Snow PB, et al. Ten-year disease
free survival after transperineal sonography-guided
iodine-125 brachytherapy with or without 45-gray external
beam irradiation in the treatment of patients with clinically
localized, low to high Gleason grade prostate carcinoma.
Cancer. 1998;83:989-1000. 3. Grimm P, Blasko J, Sylvester
J, Meier R, Cavanagh W. 10-Year biochemical (prostate-specific
antigen) control of prostate cancer with 125I brachytherapy.
Int J Radiat Oncol Biol Phys. 2001;51:31-40. 4. Data
on file. 5. Data on file. 6. Batterman JJ. Iodine-125
seed implantation for localized prostate cancer. J Brachy
Int. 1998;14:21-27. 7. Grimm P, Blasko J, Sylvester
J. Clinical selection issues for permanent seed prostate
brachytherapy. J Brachy Int. 2001;17:143-152. 8. Stock
RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A
dose-response study for I-125 prostate implants. Int
J Radiat Oncol Biol Phys. 1998;41:101-108. 9. Fuks Z,
Leibel SA, Wallner KE, Begg CB, et al. The effect of
local control on metastatic dissemination in carcinoma
of the prostate: long-term results in patients treated
with 125I implantation. Int J Radiat Oncol Biol Phys.
1991;21(3):537-547. 10. Tapen EM, Blasko JC, Grimm PD,
et al. Reduction of radioactive seed embolization to
the lung following prostate brachytherapy. Int J Radiat
Oncol Biol Phys. 1998;42:1063-1067. 11. Merrick GS,
Butler WM, Dorsey AT, Walbert HL. Prostatic conformal
brachytherapy: 125I/103Pd postoperative dosimetric analysis.
Radiat Oncol Investig. 1997;5:305-313. 12. Merrick GS,
Butler WM, Dorsey AT, Lief JH, Benson ML. Seed fixity
in the prostate/periprostatic region following brachytherapy.
Int J Radiat Oncol Biol Phys. 2000;46:215-220. 13. Sohayda
C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular
extension in localized prostate cancer. Urology. 2000;55:382-386.
14. Davis BJ, Pisansky TM, Wilson TM, et al. The radial
distance of extraprostatic extension of prostate carcinoma:
implications for prostate brachytherapy. Cancer. 1999;85:2630-2637.
15. Partin AW, Kattan MW, Subong EN, Walsh PC, et al.
Combination of prostate-specific antigen, clinical stage,
and Gleason score to predict pathological stage of localized
prostate cancer. JAMA. 1997; 277: 1445-1451.
RAPID Strand is a trademark of Oncura.
|
